Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: the case for a prospective trial.

× No keyword cloud information.

20 in total

Review 1. [Intermittent androgen deprivation as therapy for androgen-sensitive prostate cancer. Sense or nonsense?].

Authors: P Thelen; R-H Ringert; H Loertzer; A Strauß
Journal: Urologe A Date: 2012-09 Impact factor: 0.639

2. Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts.

Authors: Hung-Ming Lam; Holly M Nguyen; Mark P Labrecque; Lisha G Brown; Ilsa M Coleman; Roman Gulati; Bryce Lakely; Daniel Sondheim; Payel Chatterjee; Brett T Marck; Alvin M Matsumoto; Elahe A Mostaghel; Michael T Schweizer; Peter S Nelson; Eva Corey
Journal: Eur Urol Date: 2019-06-19 Impact factor: 20.096

3. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.

Authors: Michael T Schweizer; Emmanuel S Antonarakis; Hao Wang; A Seun Ajiboye; Avery Spitz; Haiyi Cao; Jun Luo; Michael C Haffner; Srinivasan Yegnasubramanian; Michael A Carducci; Mario A Eisenberger; John T Isaacs; Samuel R Denmeade
Journal: Sci Transl Med Date: 2015-01-07 Impact factor: 17.956

Review 4. The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer.

Authors: Michael W Drazer; Walter M Stadler
Journal: Cancer J Date: 2016 Sep/Oct Impact factor: 3.360

5. FGFR1 abrogates inhibitory effect of androgen receptor concurrent with induction of androgen-receptor variants in androgen receptor-negative prostate tumor epithelial cells.

Authors: Masashi Kobayashi; Yanqing Huang; Chengliu Jin; Yongde Luo; Tetsuji Okamoto; Fen Wang; Wallace L McKeehan
Journal: Prostate Date: 2011-03-28 Impact factor: 4.104

6. Transcription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target?

Authors: Michael C Haffner; Angelo M De Marzo; Alan K Meeker; William G Nelson; Srinivasan Yegnasubramanian
Journal: Clin Cancer Res Date: 2011-03-08 Impact factor: 12.531

7. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.

Authors: Samuel R Denmeade; John T Isaacs
Journal: Prostate Date: 2010-10-01 Impact factor: 4.104

8. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.

Authors: Chih-Pin Chuu; John M Kokontis; Richard A Hiipakka; Junichi Fukuchi; Hui-Ping Lin; Ching-Yu Lin; Chieh Huo; Chiech Huo; Liang-Cheng Su; Shutsung Liao
Journal: Cancer Sci Date: 2011-08-18 Impact factor: 6.716

9. Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells.

Authors: Chih-Pin Chuu; Rou-Yu Chen; John M Kokontis; Richard A Hiipakka; Shutsung Liao
Journal: Cancer Lett Date: 2008-11-01 Impact factor: 8.679

10. Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation.

Authors: Mohammad Hedayati; Michael C Haffner; Jonathan B Coulter; Raju R Raval; Yonggang Zhang; Haoming Zhou; Omar Mian; Emma J Knight; Nina Razavi; Susan Dalrymple; John T Isaacs; Aileen Santos; Russell Hales; William G Nelson; Srinivasan Yegnasubramanian; Theodore L DeWeese
Journal: Clin Cancer Res Date: 2016-02-01 Impact factor: 12.531